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In the last years, several studies of molecular proﬁling of aggressive lymphomas were performed. In particular, it was shown that
DLBCL can be distinguished in two diﬀerent entities according to GEP. Speciﬁcally, ABC and GCB subtypes were characterized by
having diﬀerent pathogenetic and clinical features. In addition, it was demonstrated that DLBCLs are distinct from BL. Indeed, the
latter is a unique molecular entity. However, relevant pathological diﬀerences emerged among the clinical subtypes. More recently,
microRNA proﬁling provided further information concerning BL-DLBCL distinction as well as for their subclassiﬁcation. In this
paper, the authors based on their own experience and the most updated literature review, the main concept on molecular proﬁling
of aggressive lymphomas.
1.Introduction
Burkitt lymphoma (BL) and diﬀuse large B-cell lymphoma
(DLBCL) are the commonest aggressive B-NHL worldwide
and represent distinct entities in the World Health Organiza-
tion (WHO) classiﬁcation [1, 2].
BL is listed in the WHO classiﬁcation as a single genetic
and morphologic entity with variable clinical presentation.
It accounts for 30–50% of lymphomas in children, but
only 1-2% in adults. In particular, the WHO classiﬁcation
recognizes 3 clinical subsets of BL: endemic (eBL), sporadic
(sBL), and immunodeﬁciency-associated (ID-BL) [1].
Theendemicformisthecommonesttype,beingthemost
frequent childhood cancer in equatorial Africa [1, 3–5]. eBL
isalmostinvariablyassociatedwithEpstein-Barrvirus(EBV)
infection, although local environmental toxics (i.e., Euphor-
bia tirucalli) and coinfection with arbovirus or malaria also
appear to be important for its pathogenesis [6–8].
sBListhemostcommonlyrecordedformintheUSAand
Europe. Contrary to eBL, only ∼20% of cases are correlated
to EBV [9].
Immunodeﬁciency-associated BL occurs more com-
monly in patients infected with HIV (HIV-BL). Intriguingly,
because HIV-BL can occur in patients with relatively high
CD4 counts, immunosuppression per se is not suﬃcient to
explain the relatively high prevalence of BL in this setting
[10, 11].
The diagnosis of classical BL rests on the presence of
a monotonous inﬁltrate of medium-sized blastic lymphoid
cells that show round nuclei with clumped chromatin and
multiple, centrally located nucleoli. The tumor cells have
a high proliferation rate and intermingled macrophages
containing apoptotic debris lead to the morphological aspect
of a “starry sky” pattern [1]. Immunophenotypic features
of BL include positivity of tumor cells for CD20 and CD10
(andBCL6),negativityforBCL2,andaproliferationfraction
measured by Ki-67 immunohistochemistry of nearly 100%.
On the basis of morphology, phenotype, and genetics, BL
is currently regarded as a germinal-center- (GC-) derived
neoplasm [1]. Notably, according to the somatic hypermuta-
tion (SH) patterns and the expression of speciﬁc EBV-related
molecules, in the WHO classiﬁcation, a diﬀerent origin for
the endemic and sporadic forms has been suggested [1, 12,
13].
The molecular hallmark of BL is a chromosomal rear-
rangement of MYC, in form of reciprocal translocation,
juxtaposing MYC to the immunoglobulin heavy chain (IGH
locus [(t(8; 14)(q24; q32)]) or the κ or λ light chain loci2 Advances in Hematology
(t(2; 8)(p12; q24) and t(8; 22)(q24; q11), resp.). Diﬀerent
breakpoints on chromosome 14 and diﬀerent mutation
pattern of the 5 -region of MYC have been recorded between
e B La n ds B L[ 14]. In addition, although all BLs have similar
phenotypeandMYCtranslocation,ithasbeendemonstrated
that the 3 subtypes may have diﬀerent pathogenetic mecha-
nisms and a key role for EBV has been proposed [13].
Diﬀuse large B-cell lymphoma (DLBCL) is the most
common form of lymphoma and accounts for 30–40% of
all lymphomas in adults [2]. Clinical outcome is extremely
various, with 5-year survival rates between 30% and 80%,
widely dependent on clinical risk factors and biological
heterogeneity [2]. DLBCL is characterized by the prolifer-
ation of large neoplastic B cells, with nuclear size equal
to or exceeding normal macrophage nuclei or more than
twice the size of a normal lymphocyte, that has a diﬀuse
growth pattern and comprises centroblastic, immunoblastic,
T-cell/histiocyte-rich and anaplastic morphological variants
[2]. Morphological, biological, and clinical studies have sub-
divided diﬀuse large B-cells lymphomas into morphological
variants, molecular and immunophenotypical subgroups,
and distinct disease entities.
Of note, the diﬀerential diagnosis between BL and
DLBCL is sometimes unclear, as both entities show over-
lapping morphological, immunophenotypic, and genetic
features [15]. This distinction is also often critical for the
diﬀerent management of these two diseases. In fact, rela-
tively low-dose chemotherapy regimens such as cyclophos-
phamide, doxorubicin, vincristine, and prednisone (CHOP)
aretypicallyusedtotreatDLBCL,buttheycanbeinadequate
for BL [16, 17], for which intensive chemotherapy regimens
are required [18–23]. Moreover, the characteristic t(8;14)
translocation of BL [24–26]a l s oo c c u r si n5t o1 0p e r c e n t
of cases of DLBCL [27, 28] and chromosomal breakpoints
at the MYC locus are recurrently associated with non-IG
partner loci and complex chromosomal alterations [24–32].
BecauseDLBCLismorethan20timesascommonasBL[29],
a lymphoma with a t(8;14) translocation could present a
diagnostic problem.BasedonthelastWHOclassiﬁcation, B-
cell lymphomas with features intermediate between DLBCL
a n dB Lh a v ebee nd e ﬁn ed[15] as aggressive lymphomas with
morphological and genetic features of both DLBCL and BL,
butforbiologicalandclinicalreasons,shouldnotbeincluded
in these categories. Some of these cases were previously
classiﬁed as Burkitt-like lymphoma. Most of these cases have
intermediate morphological features between DLBCL and
BL, with some cells that are smaller than typical DLBCL,
resembling BL, and some cells that are larger than typical
BL, resembling DLBCL, with a high proliferation fraction,
starry-sky pattern, and an immunophenotype consistent
with BL. Some cases may be morphologically more typical
of BL but have an atypical immunophenotype or genetic
features that preclude a diagnosis of BL. The diagnosis of
this type of unclassiﬁable B-cell lymphoma category should
not be made in cases of morphologically typical DLBCL
that have a MYC rearrangement or in otherwise typical BL
in which a MYC rearrangement cannot be demonstrated.
This is a heterogeneous category that is not yet clearly
considered a distinct disease entity, but is useful in allowing
the classiﬁcation of cases not meeting criteria for classical BL
or DLBCL [15, 30].
2. GeneExpressionof DLBCL and BL
Even with the use of current diagnostic criteria, the distinc-
tion between DLBCL and BL is not always precise; for this
reason, in the last years, diﬀerent molecular studies were
performed to further characterize DLBCL and BL.
Theﬁrstgeneexpressionproﬁling(GEP)studiesrevealed
that DLBCL is composed of at least two molecularly and
clinically distinct diseases [30, 32, 33]. The ﬁrst subgroup
of DLBCL, called germinal center B-cell-like (GCB) DLBCL,
expresses genes that are characteristic of normal germi-
nal center B cells and is characterized by frequent REL
ampliﬁcations, BCL2 translocations, and ongoing somatic
hypermutation of the immunoglobulin genes [30, 34, 35].
The second DLBCL subgroup, called activated B-cell-like
(ABC) DLBCL, misses expression of germinal center B-
cell-restricted genes and resembles mitogenically activated
blood B cells. GEP allowed to identify individual genes that
predict overall survival in DLBCL, the majority coming from
gene expression signatures that reﬂect the cell of origin,
proliferation rate, and host immune response to the tumor.
In another couple of studies, a third subgroup of DLBCL
has been deﬁned by GEP, termed primary mediastinal B-cell
lymphoma (PMBL) [31, 36]. ABC-DLBCL and PMBCL have
a constitutive activation of the nuclear factor KB (NFKB)
pathway that they require for survival, which is not a feature
of GCB-DLBCL [31, 36, 37].
These three DLBCL subgroups should be possibly con-
sidered diﬀerent entities since they correspond to diﬀerent
B-cells stages of diﬀerentiation, use diﬀerent oncogenic
pathways, and have distinct clinical behaviors [38].
These three subgroups of DLBCL are associated with a
diﬀerent clinical outcome with 5-year survival rates of 59%
inGCB-DLBCL,30%inABC-DLBCL,and64%PMBCL[30,
31, 33].
In the last years, two DNA-microarray studies investi-
gated whether global GEP might help to discern BL from
DLBCL on the molecular level [39, 40]. In the ﬁrst [40], 220
mature aggressive B-cell lymphomas that included classical
BL, “atypical BL,” and DLBC were studied. A “core group”
of eight BLs was deﬁned on the basis of WHO criteria
(histologicalclassiﬁcationofclassicor“atypical”BL,CD20+,
BCL6+, CD10+, BCL2−,C D 5 −,K I 6 7≥ 95%, and MYC
translocation). The remaining cases were compared with
the BL core group and were labeled with a “BL similarity
index” according to gene expression value of 58 genes. On
the basis of this index, aggressive B-NHL were classiﬁed
intomolecularBurkittlymphoma(mBL;22%),intermediate
cases (20%), and nonmolecular Burkitt lymphoma (non-
mBL;58%). Thedistinctive mBLsignaturewascharacterized
by 58 genes, including several target genes of the NFKB
pathway (i.e., BCL2A1, FLIP, CD44, NFKBIA, BCL3, and
STAT3) that are known to diﬀerentiate ABC or GCB
lymphomas [30, 32, 33]. These genes were expressed at lower
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signature was extended also to cases with morphological
characteristics of DLBCL and BCL2 positive. Not all cases
with a morphologic and immunophenotypical features of
BL were classiﬁed as mBL. All patients with mBL had a
favourable prognosis (5-year survival rate, 75%). Moreover,
mBL cases had very few genetic alterations, detected by
CGH, in addition to the MYC translocation (low genetic
complexity); conversely, intermediate and non-mBL cases
carried a higher number of chromosomal imbalances (high
genetic complexity). Furthermore, non-mBL (DLBCL) cases
with the MYC translocation had inferior overall survival as
compared with DLBCL cases without MYC translocation
in a retrospective analysis of patients receiving mostly a
CHOP/CHOP-like therapy [40].
In the second study [39], 303 cases with the diagnosis
of BL, “atypical” BL, and DLBCL were proﬁled for gene
expression. Aggressive B-NHL was ﬁrst divided into cases
in which a MYC target gene signature was identiﬁable
in the total gene expression proﬁle and those in which
such a signature was not evident. Expression proﬁles of
the cases that contained a MYC target gene signature were
compared with the signatures of germinal center B-cell-
like (GCB) DLBCL, activated B-cell-like (ABC) DLBCL,
and primary mediastinal lymphoma (PMBL). The gene
expression-based classiﬁer for BL includes the expression
of MYC target genes, a particular subgroup of germinal
center B-cell-associated genes, and a low expression of major
histocompatibility (MHC) class I genes and NFKB target
genes. Only when all four pairwise comparisons of the gene
expression proﬁles were in favor of the diagnosis of BL,
was the diagnosis “molecular BL” assigned. By using this
methodology, some cases that were diagnosed as DLBCL or
high-grade lymphoma were classiﬁed as BL on the basis of
gene-expression proﬁles. This molecular classiﬁer provided a
superior quantitative and reproducible diagnosis of BL to the
best actual diagnostic method.
Both gene expression studies [39, 40] conﬁrmed that
a subset of aggressive B-NHL with evident morphological
features of DLBCL showed indeed a gene expression proﬁle
of BL. Therefore, both studies help to improve the molecular
distinction between BL and DLBCL, but, at the same time,
extend the spectrum of molecular BL to some cases that
would currently be classiﬁed as DLBCL [41].
On the basis of GEP data [30, 32, 33], GCB-DLBCL
and ABC-DLBCL have a diﬀerent cellular counterpart and
a distinct clinical behavior, as patients with ABC-DLBCL
show a poorer outcome than patients with a GCB-DLBCL
[30]. Moreover, the molecular classiﬁcation may be helpful
in choosing treatments that can be eﬀective only in spe-
ciﬁc subtypes of DLBCL. Therefore, GEP can also be an
important indication in the management of the patients in
the near future. But, GEP analysis is not feasible in routine
clinical practice. For this reason, diﬀerent studies have been
made to conﬁrm GEP results using a more easy technical
approach such as immunohistochemistry (IHC). IHC can
be eﬀected in archival, formalin-ﬁxed, paraﬃn-embedded
tissues and is operable at any pathology laboratory. Diﬀerent
algorithms have been created using the expression of well-
known antigens [42–46].
None of the actual immunohistochemical algorithms is
abletoexactlypredicttheGEPsubtypeortoperfectlystratify
molecular groups with prognostic value. As a consequence,
stratiﬁcation based on immunohistochemical algorithms for
leading therapy is possible only with great caution [47].
Importantly, the 2 mentioned GEP studies on BL and
DLBCL [39, 40] did not include all BL subtypes. In a most
recent paper from our group [48], GEPs of all BL subtypes
were studied for the ﬁrst time and were compared with those
of a large panel of B-cell-derived malignancies and normal
B lymphocytes. This paper showed that BL was a distinct
entity, supporting the current WHO classiﬁcation [1]. In
fact, the GEP of all BL subtypes was quite homogeneous
and distinct from those of other lymphomas. Moreover, BL
molecular signature could eﬀectively distinguish not only
sBL but also eBL and HIV-BL from DLBCL. eBL and HIV-
BL shared a common GEPs, whereassBL cases were relatively
more diﬀerent. The principal diﬀerences between eBL and
sBL regarded signiﬁcant pathways such as BCR, TNF/NF-
KB, and interleukin-dependent intracellular cascades and
probably reﬂected the diﬀerent clinical contests. In fact, GEP
of eBL, that undergoes a chronic antigen stimulation (e.g.,
EBV, malaria, and arbovirus infections), had a molecular sig-
nature including many genes involved in immune response
regulation. Similar considerations could be then applied to
HIV-BL. Moreover, a signiﬁcant diﬀerence between eBL and
sBL also consisted in the enrichment in genes belonging to
the RBL2 network [49, 50].
Furthermore, all BL subtypes were deﬁnitely related to
GC B lymphocytes. In fact, all BL molecular proﬁles were
closer to those of GC lymphocytes than to those of memory
cells. However, it cannot be excluded that EBV + BL may
origine from a later developmental stage.
Piccaluga et al. [48] also found a large set of genes dif-
ferentially expressed in BL and normal GC cells, as a result of
malignant event. This set included genes related to immune
response, cell cycle regulation, and BCR signalling. These
diﬀerences may reﬂect the arrest of diﬀerentiation of BL
neoplastic cells and the neoplastic transformation [51].
Finally, to further validate gene expression data, immun-
ohistochemistry (IHC) was executed to evaluate the expres-
sion of proteins corresponding to genes overexpressed in
BL versus normal GC cells and according to potential
biologic interest. The 2 molecules CYR61 and SPARC tested
by IHC were strongly expressed by the neoplastic cells,
suggesting a signiﬁcant role in BL pathobiology. In fact,
CYR61 expression has been related to malignant transfor-
mation in diﬀerent settings, including human lymphomas,
being also related to aggressive clinical behavior and drug
resistance [52–54], and SPARC contributes to the acquisition
ofmigratoryandinvasivepropertiesthatarerecapitulatedby
malignant tumor cells [42].
3. microRNA inBL
Recently,miRNAshavebeenidentiﬁedasposttranscriptional
regulators of gene expression and involved in physiological
and pathological diﬀerentiation and maturation processes4 Advances in Hematology
[55]. They represent a novel mechanism that allows cells to
r e g u l a t em a n ye v e n t ss u c ha sc o n t r o lc e l lg r o w t h ,d i ﬀeren-
tiation, apoptosis, and morphogenesis [56]. Several studies
have reported the involvement of miRNAs in cancer [57–59].
In particular, in BL, several studies tried to explain some
unexplained diﬀerences between BL subtypes, for example,
MYC translocation-positiveandMYC translocation-negative
cases, EBV-positive and EBV-negative cases [60–64]. This is
a really important aspect because the MYC translocation-
negative BL cases may represent a challenging diagnosis to
discriminate them from DLBCL and from cases with inter-
mediate features between DLBCL and BL cases (DLBCL/BL)
[15, 40, 65, 66].
By using web-available resources (Mirnaviewer, Pic-Tar,
Tarbase [67], and miRBase [68]), it was possible to search
miRNA directed against a speciﬁc target, for example, MYC.
By using this methodology, Leucci et al. [63] identiﬁed
hsa-mir-34b. Hsa-mir-34b was found to be downregulated
only in BL cases that were negative for MYC translocation,
suggesting that this event might be responsible for MYC
deregulation in such cases. Hsa-mir-34b is a member of the
mir-34 family, which has been identiﬁed as a direct target of
p53 and has been observed in human cancers associated with
a p53 lack [69]. The hsa-mir-34b downregulation observed
in MYC translocation-negative cases was not associated with
mutations in the hsa-mir-34b gene sequence and probably
might be explained with other molecular mechanism. In
vitro experiments demonstrated that hsa-mir-34b had an
impact on MYC regulation. In fact, using a synthetic hsa-
mir-34b, a signiﬁcant dose-dependent decrease of MYC
was observed in lymphoblastoid cell lines and using an
hsa-mir-34b inhibitor an increase of MYC expression was
detected. These ﬁndings provided evidence for a novel
mechanism of MYC overregulation in BL cases without
the MYC translocation, as the more common aberrant
control exercised by the immunoglobulin enhancer locus.
Conversely, the overexpression of hsa-mir-34b in cases
with the MYC translocation might be due to the loss of
regulation on MYC by hsa-mir-34b itself in this condition.
In fact, hsa-mir-34b could not be eﬀective in regulating
MYC expression, as MYC is under transcriptional control of
the immunoglobulin gene promoters. These results are very
interesting because they provide a molecular signiﬁcance of
BL MYC translocation-negative cases that are often treated
as DLBCL. This study showed that MYC upregulation, due
to an alternative mechanism, represents a key role in BL
pathogenesis also in MYC translocation-negative cases.
Interestingly, MYC itself is able to activate the expression
of speciﬁc miRNAs [55, 56], suggesting the existence of
a feedback loop between MYC and speciﬁc miRNAs that
reciprocally control their expression. MYC overexpression
might induce a speciﬁc miRNA pattern that, in turn,
might be the cause of a diﬀerential gene expression and of
functional alterations of neoplastic cells [61].
In a paper by Onnis et al. [61], a strong upregulation of
hsa-miR-17-5p and hsa-miR-20a, which correlates with high
levels of MYC expression in BL, was found. Hsa-miR-9∗ was
the only miRNA strongly downregulated only in BL MYC
translocation-negative cases.
The hsa-miR-9∗ expression was tested also in DLBCL
and Intermediate DLBCL/BL cases to verify that it is a
speciﬁc molecular marker for BL cases lacking the typical
translocation.
DLBCL cases showed a strong overexpression of hsa-
miR-9∗, whereas intermediate DLBCL/BL cases showed a
heterogeneous expression, suggesting that the latter sub-
group may be considered a heterogeneous category; addi-
tional studies are necessary to demonstrate whether hsa-
miR-9∗ may be used as a speciﬁc marker to diﬀerentiate BL
from DLBCL and to identify cases that may beneﬁt from a
more aggressive therapy.
An interesting target of hsa-miR-9∗ is E2F1, which is
essential for the G1-S1 phase passage, which expression is
known to be induced by c-MYC, and in turn controls c-MYC
expression [70, 71].
Interestingly, an inverse correlation between hsa-miR-9∗
and E2F1 was found. In in vitro studies, E2F1 regulation
by hsa-miR-9∗ upregulation reduced E2F1 levels; conversely,
miR9∗ silencing induced E2F1 expression. MYC expression
was aﬀected both at the mRNA and protein levels. Thus,
hsa-miR-9∗ inactivation may determine E2F1 upregulation
and consequent MYC overexpression in BL lacking MYC
translocation. The downregulation of hsa-miR-9∗ in MYC
translocation-negative cases is caused by an epigenetic
mechanism; in fact, an aberrant methylation of hsa-miR-9-1
gene was observed in MYC translocation-negative cases. The
same epigenetic mechanism was observed in human breast
cancer [72].
Therefore, this miRNA downregulation may have an
important role in the MYC negative-translocation BL patho-
genesisandmaybecomeamolecularsignatureofthesecases,
proposing it as a novel candidate for a more careful diagnosis
and therapy.
A recent paper by Robertus et al. [64]p e r f o r m e da n
miRNA expression proﬁle of paediatric t(8; 14) positive
and high MYC expressing BL in comparison with MYC
translocation-negative mantle cell lymphoma (MCL), follic-
ular lymphoma (FL), and chronic lymphocytic leukaemia
(CLL). A normal B-cell subset was included to the study.
Unsupervised hierarchical clustering analysis showed a
unique miRNA proﬁle in BL that was a dominant MYC-
induced miRNA proﬁle with most miRNAs being downreg-
ulated. The authors observed a signiﬁcant downregulation
for hsa-let7e in BL compared to the three other NHL
subtypes. Hsa-miR-150 was also signiﬁcantly downregulated
in BL and targets MYB, which has an essential role in
haematopoietic and lymphoid development and apoptosis
[73]. Downregulation of hsa-miR-150 in BL comparedto the
other 3 NHL subtypes might thus result in enhanced MYB
levels in BL. The low expression of hsa-miR-26a, that targets
EZH2 (a member of the polycomb group of genes) [74], is
thus consistent with the previously observed high expression
of EZH2 in BL. Also, hsa-miR-155 was found downregulated
in BL. Hsa-mir-155 regulates activation-induced cytidine
deaminase (AID) expression; in fact, low expression of hsa-
mir-155, by the presence of a point mutation in the miR-
155 binding site, resulted in increased levels of AID and a
higher frequency of MYC translocations [75], consistentlyAdvances in Hematology 5
with MYC translocation-positive BL. Finally, several other
MYC-regulated miRNAs were found to be downregulated in
BL, for example, miR-23a/b targeting glutaminase, hsa-miR-
125b targeting IRF4 and PRDM1 (BLIMP1), hsa-miR-146a
targeting IRAK1 and TRAF6, and hsa-miR-223 targeting
LMO2. This study showed a speciﬁc miRNA proﬁling for BL.
Another paper by Leucci et al. [60] showed that hsa-
miR-127, which is directed against B-cell regulators, was
diﬀerentially expressed between EBV-positive and EBV-
negative BL cases. In particular, it was highly upregulated
only in EBV-positive BL samples, whereas EBV-negative
cases showed the same levels of expression with normal
controls. Thus, this upregulation may speciﬁcally depend on
the presence of EBV, though actually the mechanism of hsa-
miR-127 regulation by EBV remains unknown. The authors
proposed that hsa-miR-127 overexpression in EBV-positive
BL may determine downregulation of PRDM1 and XBP-
1, and the consequent persistence of BCL6 and germinal
center phenotype in a B cell that is already diﬀerentiated
in terms of surface immunoglobulin and mutation pattern
toward a postgerminal center B cells. This further conﬁrms
the concept of a diﬀerent pathogenetic mechanism between
EBV-positive and EBV-negative BL. In fact, the upregulation
of hsa-miR-127 may be a key event in the pathogenesis of
EBV-positive BL, by inhibiting the B-cell diﬀerentiation step.
4.microRNA inDLBCL
In the last years, several studies were performed to found
some diﬀerentially expressed miRNAs between DLBCL sub-
types.
Lawrie et al. [76] demonstrated that 3 miRNAs were
highly expressed in ABC-type but not in GCB-type cell
lines; these miRNAs (hsa-miR-155, hsa-miR-21, and hsa-
miR-221) were then conﬁrmed to be highly expressed also
in de novo DLBCL, transformed DLBCL, and follicular
lymphoma cases compared to normal B cells. According
to the cell line model, microRNAs expression levels were
greater in ABC immunophenotype DLBCL cases than in
GCB-type immunophenotype DLBCL (P<0.05). Of note,
deregulation of miR-155 appears to be a recurrent feature
of many malignancies including breast cancer [77], thyroid
carcinoma [78], and a range of solid tumors [59]. Moreover,
high-grade lymphomas were spontaneously developed by
transgenic mice expressing miR-155 targeted to B cells [79].
miR-221 has been shown to inhibit normal erythro-
poiesis through downregulation of c-kit expression [80], but
probably this gene is not a signiﬁcant target for hsa-mir-221
in DLBCL, as no evidence of c-KIT expression was detected
by IHC in DLBCL [76].
Overexpression of hsa-miR-21 resulted to be an inde-
pendent prognostic indicator from IPI status in de novo
DLBCL,andthishighexpressionwasassociatedwithabetter
prognostic outcome (P<0.05). These 3 microRNAs were
investigated also in diﬀerent developmental stages of B and
T cells from healthy individuals; both hsa-miR-155 and hsa-
miR-21 were found more highly expressed in ABC than
GCB cells. This ﬁnding advanced that high levels of these
microRNAs in DLBCL are not closely tumor associated but
may rather be correlated to a characteristic of their cell of
origin [76].
In a paper by Roehle et al. [81], the comparison of
miRNA proﬁles between DLBCL and reactive LN revealed
15 diﬀerentially expressed miRNAs. Most diﬀerentially
expressed miRNAs were downregulated (11 of 15). Hsa-
mir-210, hsa-mir-155, and hsa-mir-106A were upregulated;
conversely, expression of hsa-mir-149 and hsa-mir-139 was
reduced. As previously described, mir-155 seems to play a
critical role in B-cell maturation and lymphocyte activation
[82,83].Moreover,acorrelationbetweenmir-155andNFKB
expression was found in DLBCL cell lines and patients [84].
On the other hand, hsa-mir-210 has an important role in cell
cycle [85].
A comparison between DLBCL and FL cases showed
10 diﬀerentially expressed miRNAs. The expression of hsa-
mir-150,hsa-mir-17-5p,hsa-mir-145,hsa-mir-328,hsa-mir-
99A, hsa-mir-10A, hsa-mir-95, hsa-mir-151, and hsa-mir-
let7e was characteristic of speciﬁc DLBCL signature. Hsa-
mir-150 was highly downregulated in DLBCL and was found
toregulateB-celldevelopment [73,86].Ithasbeendescribed
thathsa-mir-10AinAMLandhsa-mir-17-5pandashsa-mir-
145 were deregulated in various other cancer types [59, 87–
90].
In addition, in a paper by Roehle et al. [81], miRNAs
with a prognostic relevance were identiﬁed. In particular,
8 miRNAs were identiﬁed by a multivariate Cox regression
analysis including IPI factors. Of these, 6 miRNAs (hsa-mir-
19A, hsa-mir-21, hsa-mir-23A, hsa-mir-27A, hsa-mir-34A,
and hsa-mir-127) were downregulated and associated with
poor EFS and/or OS. Conversely, 2 miRNAs (hsa-mir-195
and hsa-mir-let7g) were correlated to a better prognosis.
However, only hsa-mir-127 signiﬁcantly inﬂuenced both
OS and EFS in a multivariate analysis and correlated
with poor survival prognosis. Hsa-mir-127, reported to be
methylated in neoplastic cells and inversely proportional to
the expression of BCL6, plays as tumour suppressor [91].
On the contrary, hsa-mir-195 and hsa-mir-let7g, a lower
expression of which was associated to a better prognosis,
probablyfunctionasanoncomiR.Interestingly,inthispaper,
hsa-mir-155 was not identiﬁed as a prognostic marker for
survival, although this miRNA was exclusively overexpressed
in ABC-DLBCL [76, 92].
Malumbres et al. [93] provided experimental evidence
that hsa-miR-125b simultaneously downregulated expres-
sion of IRF4 and PRDM1 and had an important role in
the GC reaction and post-GC diﬀerentiation. In fact, hsa-
miR-125b expression was higher in GC centroblasts than
in memory B cells and was reciprocal to the expression
of IRF4 and PRDM1. Moreover, PRDM1 and IRF4 have
a complementary binding sites for hsa-miR-125b in the 3 
UTR region and are able to translationally repress expression
of both genes through speciﬁc interactions with this locus.
Furthermore, the authors showed that the expression of
hsa-miR-223 was low in GC lymphocytes, high in naive and
memory B cells, and reciprocal to the expression of LMO2,
that is exclusively expressed in GC lymphocytes and has a
clinical signiﬁcance in DLBCL since its expression level is6 Advances in Hematology
a powerful predictor of survival in DLBCL patients [94, 95].
Noteworthy, hsa-miR-223 was shown to be able to directly
regulate LMO2 expression.
Finally, the authors identiﬁed 9 miRNAs whose expres-
sion was most diﬀerent between the DLBCL subtypes; 2
of them (hsa-miR-155 and hsa-miR-21) were previously
reported to be diﬀerentially expressed between ABC and
GCB DLBCL subtypes [76, 96]. Overexpression of hsa-miR-
21 was conﬁrmed to be associated with a longer relapse-free
survival in a small cohort of 35 not uniformly treated de novo
in DLBCL cases. The expression level of hsa-miR-21, hsa-
miR-155,andhsa-miR-222wasalsostudiedin106R-CHOP-
treated patients of DLBCL, but only the overexpression of
hsa-miR-222, associated with ABC-DLBCL, correlated with
shorter OS and PFS. It is unknown if this correlation is
caused by a speciﬁc function in DLBCL or reﬂects the ABC
subtype [93].
5. Conclusion
In conclusion, recent GEP and miRNA proﬁling studies
providednotableinformationonthemolecularpathogenesis
of BL and DLBCL. In addition, they provided the basis
for a clear distinction of the 2 entities when morphology
and phenotype are not conclusive. Finally, the recogni-
tion of speciﬁc molecular proﬁles was useful for a more
reﬁned subclassiﬁcation of these lymphomas, with relevant
prognostic implication. Certainly, to date, it is diﬃcult to
propose global GEP in the routine workup; however, new
technologies, including next generation sequencing, will
hopefully improve our ability in the molecular managing
of lymphoma patients oﬀering adequate surrogates for
diagnosis and prognostication.
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